Invicta Medical raises $21m for sleep apnea device

Sleep apnea device developer Invicta Medical has raised approximately $21 million in a new round of equity financing, according to an SEC filing posted this week. The Palo Alto, Calif.-based company, founded in 2013, has not yet revealed the technology behind its development but claims that its solution to treating obstructive sleep apnea is non-invasive, customizable to meet patient needs and affordable, according to its website. The company has not yet officially stated how it plans to spend funds raised in the round. The round was joined by 6 anonymous investors, with the first sale in the round dated on December 20, 2017, according to the SEC filing. The post Invicta Medical raises $21m for sleep apnea device appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Respiratory invictamedical Source Type: news

Related Links:

Might obstructive sleep apnea offer protection from anesthesia-induced postoperative cognitive dysfunction by way of hypoxic preconditioning?BMC Anesthesiology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
Condition:   Coronary Artery Disease Intervention:   Diagnostic Test: Polysomnography. Sponsor:   Astes Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The United States has experienced a significant increase in obesity over the past several decades, including a substantial increase in obesity-related comorbidities, such as type 2 diabetes, hypertension, heart disease, and obstructive sleep apnea. With obesity reaching epidemic proportions, there has been an increasing need for surgical intervention as a treatment option. Bariatric procedures have not only contributed to the significant weight loss a patient may experience but they have also had a profound effect on the decrease of weight-related comorbidities.
Source: Clinics in Plastic Surgery - Category: Cosmetic Surgery Authors: Source Type: research
Conclusions:Unrecognized severe OSA was common in patients with difficult-to-control hypertension, and OSA severity was associated with myocardial injury, independent of BP control with medications.Clinical Trial Registration:Registry: ClinicalTrials.gov, Title: A Cross-sectional Study of the Occurrence and Effect of Obstructive Sleep Apnea in Subjects With Resistant Hypertension, Identifier: NCT00843583, URL:https://clinicaltrials.gov/ct2/show/NCT00843583Citation:Lui MM, Tse HF, Mak JC, Lam DC, Chan CW, Chong PW, Ip MS. Untreated obstructive sleep apnea is associated with myocardial injury independent of blood pressure co...
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Study Objectives:An oral appliance (OA) is a validated treatment for obstructive sleep apnea (OSA). However, therapeutic response is not certain in any individual and is a clinical barrier to implementing this form of therapy. Therefore, accurate and clinically applicable prediction methods are needed. The goal of this study was to derive prediction models based on multiple awake assessments capturing different aspects of the pharyngeal response to mandibular advancement. We hypothesized that a multimodal model would provide robust prediction.Methods:Patients with OSA (apnea-hypopnea index [AHI]> 10 events/h) were recru...
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Conclusions:This retrospective study illustrates that there are patients for whom PSG gave a false-negative study. Patients who had negative PSG and positive HSAT are more likely to be older and have the diagnosis of hypertension. Sleep physicians may consider repeat testing with HSAT in patients with a negative PSG and clinical symptoms of OSA.Commentary:A commentary on this article appears in this issue on page 1839.Citation:Lipatov K, Hayek A, Ghamande S, Boethel C, Chen W, Jones S. Predictors of obstructive sleep apnea on home sleep apnea test after a negative attended polysomnography.J Clin Sleep Med. 2018;14(11):1889–1894.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
We present the case of a middle-aged man with SDB and persistent AF who exhibited improvement in SDB metrics, as characterized by data downloaded from his auto-titrating continuous positive airway pressure (AutoCPAP) machine, very shortly following procedures that restored sinus rhythm. Between procedures, when his rhythm reverted to AF, the downloaded parameters suggested more SDB events. After catheter ablation, the patient maintained sinus rhythm and the improvement in SDB metrics was sustained as well. This case provides support in favor of a bidirectional relationship between SDB and AF and suggests that data availabl...
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Cochlear Ltd. (ASX:COH) has joined a $17.1 million (EU €15 million) funding round for Nyxoah to support the development and commercialization of its hypoglossal nerve stim therapy for treating obstructive sleep apnea. Australian hearing tech developer Cochlear lead the round, investing $14.7 million (EU €13 million). The round was also joined by several existing Nyxoah shareholders, the Belgian company said. As part of the funding round, a member of Cochlear has joined Nyxoah’s board of directors. “Cochlear actively monitors the market for novel technologies and implantable devices that over the ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Respiratory cochlear Nyxoah Source Type: news
Conclusion: Our results demonstrated the highest AHI during REM sleep stage in total participants after control of posture. However, there were 16.2% of patients showed NREM-dominant pattern (AHINREM/AHIREM>2) and 6.8% of patients showed higher AHISWS than AHIN1N2. Therefore, each group might have a different pathophysiology of obstructive sleep apnea (OSA), and we need to consider this point when we treat the patients with OSA. PMID: 30415523 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Otorhinolaryngology - Category: ENT & OMF Tags: Clin Exp Otorhinolaryngol Source Type: research
More News: Obstructive Sleep Apnea | Respiratory Medicine | Sleep Apnea | Sleep Disorders | Sleep Medicine | Websites